What next can we expect from cell and gene therapies? This second edition of the Cell & Gene Therapy eBook Series explores the sector's potential growth over the coming years, from expectations within the pharma industry to transformation of development processes.
Combining industry data and expert insights, we examine requirements for technological innovation in the sector including automation processes in Bioprocessing 4.0.
We also explore the uses of vectors in the gene therapy space and deep-dive into ways to tackle CMC challenges unique to gene-edited cell therapies.
1. The Future of Cell Therapy Manufacturing
Behnam Ahmadian discusses the technological progress in the cell and gene therapy industry.
2. Non-viral Delivery Methods in the Gene Therapy Industry
We examine the use of non-viral methods in gene therapy delivery according to industry data.
3. True Bioprocessing 4.0 Will Depend on Real-Time Monitoring of Product Titer
IDEX Health & Science explains how Bioprocessing 4.0 will rely on smart technology integrate all process analytical technologies (PAT) and unit operations in the production process.
4. Pharma Industry Believe Cell and Gene Therapies to Be Most Promising Therapeutics
We asked pharma professionals which sectors will achieve the most in the next 10 years.
5. CMC Challenges and Considerations for Gene-Edited Cell Therapies
Catarina Carrao explores methods in production to optimize gene-edited cell therapies.
